Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

40.83 -0.56 (-1.35%)
Streaming Delayed Price Updated: 2:25 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,183,203
Open 41.66
Bid (Size) 40.82 (800)
Ask (Size) 40.84 (300)
Prev. Close 41.39
Today's Range 40.66 - 41.79
52wk Range 31.90 - 49.62
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
Exelixis (EXEL) exemplifies GARP investing with strong oncology earnings growth, a debt-free balance sheet, and a valuation discounted versus biotech peers. 
Via Chartmill

Performance

YTD
+20.3%
+20.3%
1 Month
-5.0%
-5.0%
3 Month
+4.5%
+4.5%
6 Month
-2.3%
-2.3%
1 Year
+15.3%
+15.3%

More News

Read More
News headline image
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
From Exelixis, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Preview: Exelixis's Earnings ↗
Via Benzinga
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
News headline image
S&P 500 Surges as Congress Nears End to Protracted Government Shutdown
Via MarketMinute
Topics Economy Regulatory Compliance Stocks
News headline image
Global Markets Rally on Hopes for US Government Shutdown Resolution
Via MarketMinute
Topics Bonds Economy Government
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
What's Driving the Market Sentiment Around Exelixis Inc? ↗
Via Benzinga
News headline image
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗
Via Chartmill
News headline image
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Exelixis, Inc.
Via Business Wire
News headline image
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
From Exelixis, Inc.
Via Business Wire

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 40.83
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 12/12/25 02:25 PM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 12.86B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.